4CMenB vaccine and its role in preventing transmission and inducing herd immunity

References

• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–861.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, and Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease – population biology and evolution. Vaccine 2009;27(Suppl 2):B64–70.
   PubMed Web of Science ®Google Scholar
• McMillan M, Walters L, and Sullivan T, et al. Impact of Meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents. Clin Infect Dis. 2021;73(1):e99–e106.
   PubMed Web of Science ®Google Scholar
• De Wals P, Gilquin C, De Maeyer S, et al. Longitudinal study of asymptomatic meningococcal carriage in two Belgian populations of schoolchildren. J Infect. 1983;6(2):147–156.
   PubMed Web of Science ®Google Scholar
• Tzeng YL, and Stephens DS. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2000;2(6):687–700.
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch GH, et al. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis. 1977;9(2):105–110.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease - United States, 1996-2015. Clin Infect Dis. 2018;66(8):1276–1281.
   PubMed Web of Science ®Google Scholar
• Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034–2041.
   PubMed Web of Science ®Google Scholar
• Archer BN, Chiu CK, Jayasinghe SH, et al. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Med J Aust. 2017;207(9):382–387.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498.
   PubMed Web of Science ®Google Scholar
• Clark Sa, Borrow R. Herd protection against meningococcal disease through vaccination. Microorganisms 2020;8(11). DOI:https://doi.org/10.3390/microorganisms8111675.
   Web of Science ®Google Scholar
• Pollard AJ, and Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11–12):1327–1346.
   PubMed Web of Science ®Google Scholar
• Øvstebo R, Hellerud BC, Coureuil M, et al. Pathogenesis of invasive disease. In: Feavers I, Pollard AJ, Sadarangani Meditors. Handbook of Meningococcal Disease Management. Cham: Springer International Publishing; 2016. 25–43.
   Google Scholar
• Olsen SF, Djurhuus B, and Rasmussen K, et al. Pharyngeal carriage of Neisseria meningitidis and Neisseria lactamica in households with infants within areas with high and low incidences of meningococcal disease. Epidemiol Infect. 1991;106(3):445–457.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, and Koehler A, et al. B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents. BMJ Open. 2018;8(7):e020988.
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782.
   PubMed Web of Science ®Google Scholar
• Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009;123(3):e502–9.
   PubMed Web of Science ®Google Scholar
• Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159–1164.
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–783.
   PubMed Web of Science ®Google Scholar
• McMillan M, Wang B, Koehler AP, et al. Impact of Meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):e233–e237.
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–438.
   PubMed Web of Science ®Google Scholar
• Trotter C, Ramsay M, Harrison L. Introduction and epidemiology of meningococcal disease. In: Feavers I, Pollard AJ, Sadarangani M, editors. Handbook of Meningococcal Disease Management. Cham: Springer International Publishing; 2016. 1–14.
   Google Scholar
• Yazdankhah SP, and Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53(Pt 9):821–832.
   PubMed Web of Science ®Google Scholar
• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50 Suppl 2(S2):S37–44.
   PubMedGoogle Scholar
• Villena R, Safadi MAP, Valenzuela MT, et al. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14(5):1042–1057.
   PubMed Web of Science ®Google Scholar
• Meningococcal disease: environmental Health Indicators New Zealand; 2020 [cited 2021 Jan 20]. Available from: https://www.ehinz.ac.nz/indicators/indoor-environment/meningococcal-disease/#downloads
   Google Scholar
• Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–328.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851–861.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–366.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM, Group UKMC. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829–1831.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867–872.
   PubMed Web of Science ®Google Scholar
• MenAfriCar C. The diversity of meningococcal carriage across the african meningitis belt and the impact of vaccination with a Group A meningococcal conjugate vaccine. J Infect Dis. 2015;212(8):1298–1307.
   PubMed Web of Science ®Google Scholar
• Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969–985.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–1253.
   PubMed Web of Science ®Google Scholar
• Del Tordello E, Rappuoli R, and Delany I. Reverse vaccinology. In: Modjarrad K, and Koff WC, editors. Human Vaccines: Academic Press; 2017. 65–86 doi:https://doi.org/10.1016/B978-0-12-802302-0.00002-9.
   Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743.
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383(9911):40–47.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL. Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England. Vaccine. 2017;35(2):208–211.
   PubMed Web of Science ®Google Scholar
• Department of Health and Public Health England. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK: Department of Health and Social Care and Public Health England; 2014 [cited 2021 March Feb]. Available from: https://www.gov.uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement
   Google Scholar
• Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104.
   PubMed Web of Science ®Google Scholar
• Meningococcal B Immunisation Program: SA Health, Government of South Australia; 2020 [cited 2020 27 Apr 2020 Apr 27]. Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/immunisation/immunisation+programs/meningococcal+b+immunisation+program
   Google Scholar
• Freitas, G , Marques, JG , and Santos, SA Programa Nacional de Vacinação 2020. In: Saúde M-G, editor Lisboa: DGS: Ministério da Saúde. Direção-Geral da Saúde; 2020.
   Google Scholar
• Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Lally N, Flood L, et al. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust. 2020;212(2):89–93.
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126(5):514–521.
   PubMed Web of Science ®Google Scholar
• Marshall H, Wang B, Wesselingh S, et al. Control of invasive meningococcal disease: is it achievable? Int J Evid Based Healthc. 2016;14(1):3–14.
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Mandrell RE, Griffiss JM, et al. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979;63(5):836–848.
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–357.
   PubMed Web of Science ®Google Scholar
• Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13(10):605–619.
   PubMed Web of Science ®Google Scholar
• Zariri A, Beskers J, van de Waterbeemd B, et al. Meningococcal outer membrane vesicle composition-dependent activation of the innate immune response. Infect Immun. 2016 Oct;84(10):3024–3033.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. Jama. 1999 Apr 28;281(16):1520–1527.
   PubMed Web of Science ®Google Scholar
• Marsay L, Dold C, Green CA, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: a phase I clinical trial. J Infect. 2015 Sep;71(3):326–337.
   PubMed Web of Science ®Google Scholar
• Wedege E, Kuipers B, Bolstad K, et al. Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect Immun. 2003 Jul;71(7):3775–3781.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, and Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991 Dec;14(2):195–207; NIPH Ann.
   Google Scholar
• Cassio de Moraes J, Camargo MCC, Rossetto HNT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340(8827):1074–1078.
   PubMed Web of Science ®Google Scholar
• Ochoa-Azze RF. Cross-protection induced by VA-MENGOC-BC(R) vaccine. Hum Vaccin Immunother. 2018 May 4;14(5):1064–1068.
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–1096.
   PubMed Web of Science ®Google Scholar
• Caron F, Du Chatelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011 Jun;11(6):455–463.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother. 2018 May 4;14(5):1058–1063.
   PubMed Web of Science ®Google Scholar
• Arnold R, Galloway Y, McNicholas A, et al. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011 Sep 16;29(40):7100–7106.
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009 Apr;38(2):413–418.
   PubMed Web of Science ®Google Scholar
• Delbos V, Lemee L, Benichou J, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine. 2013 Sep 13;31(40):4416–4420.
   PubMed Web of Science ®Google Scholar
• Holmes JD, Martin D, Ramsay C, et al. Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. Epidemiol Infect. 2008;136(6):790–799.
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Bjune G, and Feiring B, et al. Changes in carrier status of Neisseria meningitidis in teenagers during a group B outer membrane vaccination trial in Norway. In: Conde-Glez CJ, Morse S, and Rice P, et al. editors. Pathobiology and Immunobiology of Neisseriaceae. Cuernavaca, Morelos. Mexico: Instituto Nacional de Salud Publica; 1994. p. 895–901.
   Google Scholar
• Masignani V, Pizza M, Moxon ER. The development of a vaccine against Meningococcus B using reverse vaccinology. Front Immunol. 2019;10:751.
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30 Suppl 2(2):B87–97.
   PubMedGoogle Scholar
• Shirley M, Taha MK. MenB-FHbp Meningococcal Group B Vaccine (Trumenba((R))): a review in active immunization in individuals aged >/= 10 years. Drugs. 2018;78(2):257–268.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with Meningococcal Group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Campbell H, Andrews N, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa1244.
   Google Scholar
• Comanducci M, Bambini S, and Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445–1454.
   PubMed Web of Science ®Google Scholar
• Pajon R, Lujan E, Granoff DM. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine. 2016;34(5):643–649.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Block SL, Jackowska T, et al. Immune responses to booster vaccination with Meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines. A Phase 2 randomized study. Pediatr Infect Dis J. 2018;37(5):475–482.
   PubMed Web of Science ®Google Scholar
• Pfizer announces start of four phase 3 clinical trials for investigational vaccines: Pfizer Inc; 2020 [Cited 2021 October Feb]. Available from: https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Start-of-Four-Phase-3-Clinical-Trials-for-Investigational-Vaccines/default.aspx
   Google Scholar
• Study to Assess Effectiveness of GlaxoSmithKline’s (GSK’s) Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults.: clinicalTrial.gov, U.S. National Library of Medicine; 2021 [Cited 2021 September Feb]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04502693
   Google Scholar
• Men ABCWY Noninferiority Study in Healthy Participants ≥10 to <26 years of age: clinicaltrials.gov, U.S. National Library of Medicine.; 2021 [Cited 2021 October Feb]. Available from: https://clinicaltrials.gov/ct2/show/NCT04440163
   Google Scholar
• Nymark LS, Sharma T, Miller A, et al. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine. 2017;35(49 Pt B):6828–6841.
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Jackson S, Balmer P, et al. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020;20(1):1890.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56(3):354–363.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Finn A. Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J Clin Pathol. 2004;57(10):1015–1021.
   PubMed Web of Science ®Google Scholar
• Khalil M, Al-Mazrou Y, Findlow H, et al. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine. Vaccine. 2014 Sep 29;32(43):5715–5721.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Choo S, Everard J, et al. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun. 2000 May;68(5):2692–2697.
   PubMed Web of Science ®Google Scholar
• Roche AM, Richard AL, Rahkola JT, et al. Antibody blocks acquisition of bacterial colonization through agglutination. Mucosal Immunol. 2015 Jan;8(1):176–185.
   PubMed Web of Science ®Google Scholar
• Barnes GK, Workalemahu B, Kristiansen PA, et al. Salivary and serum antibody response against neisseria meningitidis after vaccination with conjugate polysaccharide vaccines in Ethiopian volunteers. Scand J Immunol. 2016 Aug;84(2):118–129.
   PubMed Web of Science ®Google Scholar
• Stoof SP, van der Klis FR, van Rooijen DM, et al. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool. Vaccine. 2015 Jul 31;33(32):3933–3939.
   PubMed Web of Science ®Google Scholar
• van Ravenhorst MB, Den Hartog G, van der Klis FRM, et al. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. PLoS One. 2018;13(4):e0191261.
   PubMed Web of Science ®Google Scholar
• Vianzon V, Illek B, and Moe GR. Effect of vaccine-elicited antibodies on colonization of Neisseria meningitidis Serogroup B and C strains in a human bronchial epithelial cell culture model. Clin Vaccine Immunol. 2017 Oct;24(10):e00188–17.
   PubMedGoogle Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and Meningococcal carriage in adolescents in Australia. N Engl J Med. 2020 Jan 23;382(4):318–327.
   PubMed Web of Science ®Google Scholar
• Buckwalter CM, Currie EG, Tsang RSW, et al. Discordant effects of licensed Meningococcal Serogroup B vaccination on invasive disease and nasal colonization in a humanized mouse model. J Infect Dis. 2017 May 15;215(10):1590–1598.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: bIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124.
   PubMedGoogle Scholar
• Caugant DA. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect Genet Evol. 2008 Sep;8(5):558–565.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt S, Muller A, and Sillmann H, et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol. 1996 Jun;20(6):1211–1220.
   PubMed Web of Science ®Google Scholar
• Tzeng YL, Thomas J, and Stephens DS. Regulation of capsule in Neisseria meningitidis. Crit Rev Microbiol. 2016 Sep;42(5):759–772.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev. 2007 Jan;31(1):52–63.
   PubMed Web of Science ®Google Scholar
• Jordens JZ, Williams JN, and Jones GR, et al. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect Immun. 2004 Nov;72(11):6503–6510.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969 Jun 1;129(6):1327–1348.
   PubMed Web of Science ®Google Scholar
• Alamro M, Bidmos FA, Chan H, et al. Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage. Infect Immun. 2014 Jun;82(6):2472–2484.
   PubMed Web of Science ®Google Scholar
• Litt DJ, Savino S, and Beddek A, et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis. 2004 Oct 15;190(8):1488–1497.
   PubMed Web of Science ®Google Scholar
• Breakwell L, Whaley M, Khan UI, et al. Meningococcal carriage among a university student population - United States, 2015. Vaccine. 2018 Jan 2;36(1):29–35.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university Serogroup B Meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis. 2017;216(9):1130–1140.
   PubMed Web of Science ®Google Scholar
• Miglietta A, Innocenti F, and Pezzotti P, et al. Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: a cross-sectional study. BMC Infect Dis. 2019 Jan 8;19(1):29.
   PubMedGoogle Scholar
• Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a Serogroup B Meningococcal disease outbreak and mass vaccination campaign at a college - Rhode Island, 2015-2016. Clin Infect Dis. 2017 Apr 15;64(8):1115–1122.
   PubMed Web of Science ®Google Scholar
• van Ravenhorst MB, Bijlsma MW, van Houten MA, et al. Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. Clin Microbiol Infect. 2017 Aug;23(8):573e1–573 e7.
   Web of Science ®Google Scholar
• Watle SV, Caugant DA, Tunheim G, et al. Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors. Epidemiol Infect. 2020;148:e80.
   PubMed Web of Science ®Google Scholar
• McMillan M, Walters L, Mark T, et al. B Part of It study: a longitudinal study to assess carriage of Neisseria meningitidis in first year university students in South Australia. Hum Vaccin Immunother. 2019;15(4):987–994.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006 Jun;12(6):950–957.
   PubMed Web of Science ®Google Scholar
• Diaz J, Carcamo M, Seoane M, et al. Prevalence of meningococcal carriage in children and adolescents aged 10-19 years in Chile in 2013. J Infect Public Health. 2016 Jul-Aug;9(4):506–515.
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Rodrigues CMC, Bratcher HB, et al. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results. Lancet Infect Dis. 2021 May;21(5):677–687.
   PubMed Web of Science ®Google Scholar
• Cooper LV, Kristiansen PA, Christensen H, et al. Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis. Epidemiol Infect. 2019Jan;147:e228.
   PubMed Web of Science ®Google Scholar
• Tefera Z, Mekonnen F, and Tiruneh M, et al. Carriage rate of Neisseria meningitidis, antibiotic susceptibility pattern and associated risk factors among primary school children in Gondar town, Northwest Ethiopia. BMC Infect Dis. 2020 May 20;20(1):358.
   PubMed Web of Science ®Google Scholar
• Peterson ME, Li Y, Shanks H, et al. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open. 2019 Apr 20;9(4):e024343.
   PubMed Web of Science ®Google Scholar
• Kim HW, Lee S, and Kwon D, et al. Characterization of oropharyngeal carriage isolates of Neisseria meningitidis in healthy Korean adolescents in 2015. J Korean Med Sci. 2017 Jul;32(7):1111–1117.
   PubMed Web of Science ®Google Scholar
• Gonzales ML, Bianco V, Vyse A. Meningococcal carriage in children and young adults in the Philippines: a single group, cross-sectional study. Epidemiol Infect. 2017 Jan;145(1):126–132.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014 Dec 13;384(9960):2123–2131.
   PubMed Web of Science ®Google Scholar
• Carr J, Plested E, Aley P, et al. ‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open. 2020 22;10(10):e037358.
   PubMed Web of Science ®Google Scholar
• McMillan M, Chandrakumar A, and Wang HLR, et al. Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis. Clin Infect Dis. 2020;73(3): e609–e619 .
   Web of Science ®Google Scholar
• Be on the TEAM: teenagers against meningitis; ISRCTN75858406: BioMed Central; [cited 2021 May Feb]. doi:https://doi.org/10.1186/ISRCTN75858406
   Google Scholar
• Marshall HS, McMillan M, and Koehler A, et al. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis. BMJ Open. 2019 May 6;9(5):e027233.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, and Koehler AP, et al. Reduction in carriage of Neisseria meningitidis group W following implementation of meningococcal B and meningococcal ACWY vaccines in South Australian adolescents 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 26-29 October 20202020.
   Google Scholar
• Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38(47):7558–7568.
   PubMed Web of Science ®Google Scholar
• Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015 May 15;33(21):2500–2510.
   PubMed Web of Science ®Google Scholar